David M. Loeb

David M. Loeb

Auto-generated profile, based on publicly available information

David M. Loeb

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
OAOla Awad
Ola Awad
JYJason T. Yustein
Jason T. Yustein
PSPreeti Shah
Preeti Shah
NGNaheed Gul
Naheed Gul
VKVaralakshmi Katuri
Varalakshmi Katuri
DLDavid M. Loeb
David M. Loeb
Cancer stem cells are a chemotherapy-resistant population capable of self-renewal and of regenerating the bulk tumor, thereby causing relapse and patient death. Ewing's sarcoma, the second most common form of bone tumor in adolescents and young adults, follows a clinical pattern consistent with the Cancer Stem Cell model – remission is easily achieved, even for patients with metastatic disease, but relapse remains frequent and is usually fatal. We have isolated a subpopulation of Ewing's sarcoma cells, from both human cell lines and human xenografts grown in immune deficient mice, which express high aldehyde dehydrogenase (ALDHhigh) activity and are enriched for clonogenicity, sphere-formation, and tumor initiation. The ALDHhigh cells are resistant to chemotherapy in vitro, but this can be overcome by the ATP binding cassette transport protein inhibitor, verapamil. Importantly, these cells are not resistant to YK-4-279, a small molecule inhibitor of EWS-FLI1 that is selectively toxic to Ewing's sarcoma cells both in vitro and in vivo. Ewing's sarcoma contains an ALDHhigh stem-like population of chemotherapy-resistant cells that retain sensitivity to EWS-FLI1 inhibition. Inhibiting the EWS-FLI1 oncoprotein may prove to be an effective means of improving patient outcomes by targeting Ewing's sarcoma stem cells that survive standard chemotherapy.

1 June 2008 in Surgical Clinics of North America
Verified
Journal Article
Closed access
DLDavid M. Loeb
David M. Loeb
KTKatherine Thornton
Katherine Thornton
OSOri Shokek
Ori Shokek

31 March 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
SGSeth D. Goldstein
Seth D. Goldstein
MTMatteo Trucco
Matteo Trucco
WGWendy Bautista Guzman
Wendy Bautista Guzman
MHMasanori Hayashi
Masanori Hayashi
DLDavid M. Loeb
David M. Loeb
A monoclonal antibody against the Wnt signaling inhibitor dickkopf-1 inhibits osteosarcoma metastasis in a preclinical model

28 June 2016 in Cancer
Verified
Journal Article
Open access
PDF file
MHMasanori Hayashi
Masanori Hayashi
DCDavid Chu
David Chu
CMChristian F. Meyer
Christian F. Meyer
NLNicolas J. Llosa
Nicolas J. Llosa
GMGregory McCarty
Gregory McCarty
DLDavid M. Loeb
David M. Loeb
BACKGROUND: Even though virtually all patients with Ewing sarcoma achieve a radiographic complete response, up to 30% of patients who present with localized disease and up to 90% of those who present with metastases experience a metastatic disease recurrence, highlighting the inability to identify patients with residual disease at the end of therapy. Up to 95% of Ewing sarcomas carry a driving EWS‐ETS translocation that has an intronic breakpoint that is specific to each tumor, and the authors developed a system to quantitatively detect the specific breakpoint DNA fragment in patient plasma.METHODS: The authors used a long‐range multiplex polymerase chain reaction (PCR) technique to identify tumor‐specific EWS‐ETS breakpoints in Ewing sarcoma cell lines, patient‐derived xenografts, and patient tumors, and this sequence was used to design tumor‐specific primer sets to detect plasma tumor DNA (ptDNA) by droplet digital PCR in xenograft‐bearing mice and patients.RESULTS: Tumor‐specific breakpoint DNA fragments were detected in the plasma of xenograft‐bearing mice, and the signal correlated with tumor burden during primary tumor growth, after surgical resection, and at the time of metastatic disease recurrence. Furthermore, the authors were able to detect the specific breakpoint in plasma DNA obtained from 3 patients with Ewing sarcoma and in 2 patients the authors were able to detect ptDNA when there was radiographically undetectable disease present.CONCLUSIONS: The use of droplet digital PCR to detect tumor‐specific EWS‐ETS fusion gene breakpoint ptDNA fragments can be developed into a highly personalized biomarker of disease recurrence that can be optimized in animal studies for ultimate use in patients. Cancer 2016;122:3015‐3023. © 2016 American Cancer Society.

24 August 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
MHMasanori Hayashi
Masanori Hayashi
PZPeixuan Zhu
Peixuan Zhu
GMGregory McCarty
Gregory McCarty
CMChristian F. Meyer
Christian F. Meyer
CPChristine A. Pratilas
Christine A. Pratilas
DLDavid M. Loeb
David M. Loeb
Size-based detection of sarcoma circulating tumor cells and cell clusters Size-based detection of sarcoma circulating tumor cells and cell clusters

20 March 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GMGregory McCarty
Gregory McCarty
DLDavid M Loeb
David M Loeb
WT1 is a transcription factor expressed in hematopoietic stem cells and in most cases of myeloid leukemia. We investigated the roles of hypoxia and epigenetics in the regulation of WT1 expression in myeloid leukemia cells. WT1 expression correlates with hypomethylation of the CpG island in Intron 1, and pharmacologic demethylation of this CpG island induces WT1 mRNA expression. Hypoxia causes decreases in DNMT expression and activity and increased expression and activity of TET2 and TET3, resulting in demethylation of this CpG island and expression of WT1 mRNA. Demethylation of the CpG island, either from pharmacologic treatment or induction of hypoxia, results in transcription of an antisense-oriented lncRNA, and inhibiting lncRNA expression with shRNA blocks WT1 mRNA expression. These results reveal a novel model of hypoxia-mediated epigenetic gene regulation. In addition, this is the first report that TET2 and TET3, increasingly recognized as important epigenetic regulators of gene expression in stem cells and in cancer cells, can be regulated by hypoxia, providing a solid mechanistic link between hypoxia and epigenetic regulation of gene expression with important implications for the role of hypoxia in stem cell function.